VTGN Deadline: VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit

Core Viewpoint - Vistagen Therapeutics, Inc. (NASDAQ: VTGN) is facing a securities fraud lawsuit, with a lead plaintiff deadline set for March 16, 2026, for investors who purchased common stock between April 1, 2024, and December 16, 2025 [1] Group 1: Lawsuit Details - The lawsuit alleges that Vistagen provided misleading information regarding its drug fasedienol, which is in development for treating social anxiety disorder (SAD) [1] - Defendants reportedly made positive assertions about fasedienol's trial success based on prior results from the PALISADE-2 clinical trial, while concealing adverse facts about the Phase 3 PALISADE-3 trial [1] - Investors are claimed to have suffered damages when the true details about the trial were revealed [1] Group 2: Legal Representation - The Rosen Law Firm is encouraging investors to join the class action and emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [1] - The firm has a history of significant recoveries for investors, including over $438 million in 2019 alone [1] - Investors can join the class action without any out-of-pocket fees through a contingency fee arrangement [1]